Is LifeVantage Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for LifeVantage Corp. has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company appears undervalued, supported by a P/E ratio of 17, a PEG ratio of 0.11, and an EV to EBITDA ratio of 8.48, which are significantly more favorable compared to its peers. For instance, Chromadex Corp. has a much higher P/E of 39.82, while USANA Health Sciences, Inc. shows an EV to EBITDA of 4.73, highlighting LifeVantage's relative attractiveness in the market.
Despite recent underperformance, with a year-to-date return of -49.74% compared to the S&P 500's 13.30%, LifeVantage's strong fundamentals, including a remarkable ROCE of 96.19% and a solid ROE of 26.91%, suggest that it may be poised for recovery. Overall, the combination of favorable valuation ratios and strong operational metrics supports the conclusion that LifeVantage Corp. is undervalued in the current market landscape.